The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents with HIV is Accepting Applications for Scientific/Clinical Members
The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting applications for new scientific/clinical members with expertise in HIV medicine. The Panel is seeking candidates with expertise in HIV clinical research and clinical care, with a focus on the following areas:
- Adolescent Medicine
- Antiretroviral Therapy
- Drug Resistance and Virologic Failure
- Metabolic Complications of HIV
- Tuberculosis and HIV Co-Infection
Panel members critically evaluate new information and prepare guideline revisions. The candidates should be recognized experts in their areas of interest. The successful candidates will serve a 4-year term beginning September 2024, with potential for reappointment for an additional term.
The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of over 40 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via videoconferencing to review and critically evaluate emerging scientific data relating to antiretroviral therapy and to revise the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.
Panel members are not financially compensated for their time commitment. Panel members are required to report any relationship with companies involved with antiretroviral agents or diagnostic tests relevant to antiretroviral treatment. Panel members are not allowed to be part of a pharmaceutical company’s speaker bureau.
The Panel encourages applications from candidates of diverse backgrounds. The application should include a curriculum vitae and a letter of interest. The letter should have specific reference to how the applicant would contribute to the work of the Panel, especially in the areas noted above. All supporting documents should be submitted to Alice Pau, Pharm.D. (apau@niaid.nih.gov) or Marylu Schaffhauser (marylu.schaffhauser@nih.gov) electronically by May 24, 2024.